Stocks · News reference
ARK Investment Management Trims Position in Twist Bioscience
Recent 13F regulatory filings indicate that ARK Investment Management reduced its holdings in Twist Bioscience Corporation.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wall Street Analysts Update Ratings and Price Targets for Twist Bioscience
Multiple financial institutions updated their ratings and price targets for Twist Bioscience on November 14, 2026, with targets ranging from $135 to $175.
Baird Maintains Buy Rating on Twist Bioscience and Raises Price Target to $135
Baird analyst Catherine Ramsey Schulte has maintained a Buy rating on Twist Bioscience while increasing the price target from $115 to $135.
Canaccord Genuity Cuts Twist Bioscience Price Target to $150
Canaccord Genuity has reduced its price target for Twist Bioscience shares from $205 to $150.
TD Cowen Maintains Buy on Twist Bioscience, Lowers Price Target to $137
Analysts Adjust Price Targets for Twist Bioscience
Following the company's fiscal fourth-quarter earnings report, Guggenheim and BofA Securities lowered their price targets for Twist Bioscience Corporation.